← FDA DRUG APPROVALS
FDA ANDA · ANDA091616
LITHIUM CARBONATE ER
lithium carbonate
Sponsor: GLENMARK PHARMS LTD
APPLICATION
ANDA091616
TYPE
ANDA
ORIGINAL APPROVAL
2011-02-14
LATEST ACTION
2022-10-13
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription
Products
LITHIUM CARBONATEPrescription
LITHIUM CARBONATE 450MG · TABLET, EXTENDED RELEASE · ORAL
Approval history
2022-10-13Labeling · Supplement 12 · standardAP
2020-02-05Labeling · Supplement 9 · standardAP
2018-12-20Labeling · Supplement 8 · standardAP
2018-12-07Labeling · Supplement 7 · standardAP
2011-02-14OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.